Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9949518 | 1.00 | ALDH1A1 (0.54) | ALDH1A1KMT2AMEN1KDM4EL3MBTL1 | |
| SCHEMBL8271235 | 0.90 | POLB (0.44) | ALDH1A1KMT2AMEN1KDM4EL3MBTL1 | |
| SCHEMBL14949558 | 0.86 | ALDH1A1 (0.55) | ALDH1A1KMT2AMEN1KDM4EL3MBTL1 | |
| SCHEMBL4002663 | 0.83 | ALDH1A1 (0.48) | ALDH1A1KMT2AMEN1GRM3CREBBP | |
| SCHEMBL3284527 | 0.83 | ALDH1A1 (0.39) | ALDH1A1KMT2AMEN1KDM4EL3MBTL1 | |
| SCHEMBL12182476 | 0.81 | MEN1 (0.58) | ALDH1A1KMT2AMEN1KDM4ECREBBP | |
| SCHEMBL13010 | 0.80 | ALDH1A1 (0.65) | ALDH1A1KMT2AMEN1KDM4EL3MBTL1 | |
| SCHEMBL12922 | 0.80 | ALDH1A1 (0.65) | ALDH1A1KMT2AMEN1KDM4EL3MBTL1 | |
| SCHEMBL20698377 | 0.80 | ALDH1A1 (0.46) | ALDH1A1KMT2AMEN1KDM4EL3MBTL1 | |
| SCHEMBL20698378 | 0.80 | ALDH1A1 (0.46) | ALDH1A1KMT2AMEN1KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-06-28 | — | — | US | claimed |
| EP-2473505-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2012-07-11 | — | — | EP | disclosed |
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | CDK4, CDK1, CCNI | ALDH1A1 1528/4885KMT2A 611/4885MEN1 1282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.